Browse > Article

Effect of interleukin-2 on antitumor response against intraperitoneal RD-995 tumor in mice  

권오덕 (전북대학교 수의과대학)
Publication Information
Korean Journal of Veterinary Service / v.25, no.3, 2002 , pp. 309-314 More about this Journal
Abstract
Recombinant interleukin-2(IL-2) has demonstrated as an antineoplastic agent in mice and human, but the relatively low response rates observed in clinical trials. Therefore, the present study was undertaken in order to evaluate therapeutic activities of IL-2 for the establishment of therapeutic applications. At the onset of the experiment, normal C3H/HeN mice were injected with 5$\times$10$\^$6/ RD-995 tumor cells, murine ultraviolet radiation-induced fibrosarcoma, intraperitoneally. Beginning on day 6, experimental groups were treated with a 5-day course of IL-2(subcutaneous injection of 30,000 IU every 12 hours for 5 days). The result of this experiment revealed that body weight gradually decreased from 20th day in control mice. Subcutaneous IL-2 therapy prevented partially decrease body weight, and prolonged survival of mice compared with control group.
Keywords
Interleukin-2; RD-995 tumor; Antitumor effect; Mice;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rosenberg SA, Lotze MT, Mule JJ 1988. New approach to the immunotherapy of cancer using interleukin-2. Ann Int Med 108 : 853-864
2 Brandau S, Suttmann H, Flad HD, et al. 2000. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2-and BCG-activated effector cells. Cancer Immunol Immunother 49 : 369-376
3 Dutcher JP, Logan T, Gordon M, et al. 2000. Phase II trial of interleukin 2, interferon alpha. and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 6 : 3442-3450
4 Thomson A. 1991. Interleukin-2. In : The cytokine handbook. Academic Press. London : 83-102
5 Paul WE. 1993. T-cell derived cytokines and their receptors. In: Fundamental immunology, 3rd ed. Raven Press. New York : 763-800
6 Boccoli G, Masciulli R, Ruggeri EM, et al. 1990. Adoptive immunotherapy of human cancer. The cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment. Cancer Res 50 : 5795-5800
7 Hibbs JB Jr, Taintor RR, Vavrin Z, et al. 1988. Nitric oxide. A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157 : 87-94
8 해리슨내과학편찬위원회. 1997. Harrison's 내과학, 서울. 도서출판 정담 : 1977-1993
9 Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 : 457
10 Kalbfleisch JD, Prentice RL. 1980. The statistical analysis of failure time data. John Wiley & Sons. New York: 143
11 Lotze MT, Grimn EA. Mazumder A, et al. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41 : 4420-4425
12 Kasid A, Director EP, Rosenberg SA. 1989. Induction of endogeneous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 143: 736-739
13 Jansson OT, Morcos E, Brundin L, et al. 1998. Nitric oxide synthase activity in human renal cell carcinoma. J Urol 160 : 556-560
14 Kwon OD. 2000. Effect of interleukin-2 on antitumor response against subcutaneous Meth-A tumor in mice. Korean J Vet Clin Med 17: 305-310
15 Whittington R, Faulds D. 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46 : 446-514
16 Margolin KA. 2000. Interleukin-2 in the treatment of renal cancer. Semin Oncol 27 : 194-203
17 Mertelsmann R, Welte K. 1986. Human interleukin-2 molecular biology. physiology and clinical possibilities. Immunol 172 : 400-419
18 Mier JW, Vachino G, Van Der Meer JWM, et al. 1988. Induction of circulating tumor necrosis factor(TNF-$\alpha$) as the mechanism for the febrile response to interleukin-2(IL-2) in cancer patients. J Clin Immunol 8 : 426-436
19 Kwon OD. 2001. Effect of interleukin-2 on antitumor response against ultraviolet radiation-induced fibrosarcoma in mice. J Vet Clin Med 18: 14-17
20 Kripke ML. 1977. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37 : 1395-1400
21 Anderson PM, Sorenson MA. 1994. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 27 : 19-31
22 Gelmo BT, Palladino MA Jr, Jeffe HS, et al. 1988. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5864-5867
23 Lee SG, Hea DS, Yoon SJ, et al. 2000. Effect of GM-CSF and IL-2 coexpression on the anti-tumor immune response. Anticancer Res 20 : 2681-2686
24 Blay JY, Favrot MC, Negrier S, et al. 1990. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50 : 2371-2374
25 Yim CY, McGregor JR, Kwon OD, et al. 1995. Nitric oxide synthesis contributes to IL-2-induced antitumor response against intraperitoneal Meth A tumor. J Immunol 155: 4382-4390
26 Cifone MG, D'Alo S, Parroni R, et al. 1999. Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production. Blood 93 : 3876-3884
27 Robak T. 1995. Biological properties and therapeutic use of interleukin 2(IL-2). Postepy Hig Med Dosw 49: 367-393
28 Yim CY, Lee CW, Choi SM, et al. 1996. Effects of nitric oxide(NO) synthesis inhibition on antitumor responses during interleukin-2(IL-2) treatment of mice. Korean J Intern Med 11 : 93-100
29 Hibbs JB Jr, Westenfelder C, Taintor RR, et al. 1992. Evidence for cytokine inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy. J Clin Invest 89 : 867-877
30 Jyothi MD, Khar A. 2000. Interleukin-2-induced nitric oxide synthase and nuclear factor-kappa B activity in activated natural killer cells and the production of interferon-gamma. Scand J Immunol 52 : 148-155
31 Papa MZ, Vetto JT, Ettinghausen SE, et al. 1986. Effect of corticosteroid on the antitumor actrvity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res 46: 5618-5623
32 Samlowski WE, Yim CY, McGregor JR, et al. 1995. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL- 2 treatment of mice. J Immunother 18: 166- 178
33 Yim CY, Bastian NR, Smith JC, et al. 1993. Macrophage nitric oxide synthesis delays progression of ultraviolet light induced murine skin cancers. Cancer Res 55 : 5507-5511